Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Tislelizumab

Review the clinical trials studying tislelizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-18 of 18

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Status: Active
Location: 8 locations
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: 5 locations
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Status: Active
Location: 6 locations
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Status: Active
Location: 4 locations
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Status: Active
Location: 4 locations
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Status: Active
Location: 4 locations
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
Tislelizumab Before and After Radiation Therapy for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: 2 locations
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Tislelizumab and Pamiparib in Combination with Concurrent Chemotherapy and Radiation Therapy for the Treatment of Patients with Previously Treated Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
Status: Enrolling by Invitation
Location: 6 locations
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Tislelizumab for the Treatment of Patients with Mismatch Repair Deficient Metastatic Colorectal Cancer or Stage II or III Rectal Cancer
Status: Approved
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Fruquintinib and Tislelizumab for the Treatment of Colorectal Cancer in Patients with Minimal Residual Disease after Chemotherapy Treatment
Status: Approved
Location: M D Anderson Cancer Center, Houston, Texas